 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | topical (ophthalmic) |
| ATC code |
|
| Pharmacokinetic data | |
| Eliminationhalf-life | 20 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H29NO3 |
| Molar mass | 307.434 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Levobetaxolol is a drug used to lower thepressure in the eye in treating conditions such asglaucoma. It is marketed as a 0.25 or 0.5%ophthalmic solution of levobetaxolol hydrochloride under thetrade nameBetaxon. Levobetaxolol is abeta-adrenergicreceptor inhibitor (beta blocker).
It is indicated for intraocular pressure reduction in patients withopen-angle glaucoma orocular hypertension.[1]
Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It also has neuroprotective effects.[1] Levobetaxolol has fewer cardiovascular side effects than other beta blockers.
Levobetaxolol should not be used by people who havesinus bradycardia,atrioventricular block, cardiogenic shock, or overt cardiac failure. The drug has been associated withbradycardia andhypertension.[citation needed]
Levobetaxolol was developed in the 1980s.[1] It was FDA approved in 2000.[2]
